Company: DERM
Filing Date: 2025-08-28
Form Type: 424B3
Source: 0001104659-25-084876
Chunk: 45

Company: Journey Medical Corp
Filing Date: 2025-08-28
Form: 424B3
Chunk 45
---
 may then resell the securities to
the public at varying prices to be determined by the dealer at the time of resale.

If we utilize an underwriter in the sale of the
securities being offered by this prospectus, we will execute an underwriting agreement with the underwriter at the time of sale, and we
will provide the name of any underwriter in the prospectus supplement which the underwriter will use to make re-sales of the securities
to the public. In connection with the sale of the securities, we, or the purchasers of the securities for whom the underwriter may act
as agent, may compensate the underwriter in the form of underwriting discounts or commissions. The underwriter may sell the securities
to or through dealers, and the underwriter may compensate those dealers in the form of discounts, concessions or commissions.

With respect to underwritten public offerings,
negotiated transactions and block trades, we will provide in the applicable prospectus supplement information regarding any compensation
we pay to underwriters, dealers or agents in connection with the offering of the securities, and any discounts, concessions or commissions
allowed by underwriters to participating dealers. Underwriters, dealers and agents participating in the distribution of the securities
may be deemed to be underwriters within the meaning of the Securities Act, and any discounts and commissions received by them and any
profit realized by them on resale of the securities may be deemed to be underwriting discounts and commissions. We may enter into agreements
to indemnify underwriters, dealers and agents against civil liabilities, including liabilities under the Securities Act, or to contribute
to payments they may be required to make in respect thereof.

We may authorize agents or underwriters to solicit
offers by certain types of institutional investors to purchase securities from us at the public offering price set forth in the applicable
prospectus supplement pursuant to delayed delivery contracts providing for payment and delivery on a specified date in the future. We
will describe the conditions to these contracts and the commissions we must pay for solicitation of these contracts in the prospectus
supplement.

Shares of our common stock sold pursuant to the
registration statement of which this prospectus is a part will be authorized for listing and trading on the Nasdaq Capital Market. The
applicable prospectus supplement will contain information, where applicable, as to any other listing, if any, on the Nasdaq Capital Market
or any securities market or other securities exchange of the securities covered by the prospectus supplement. We can make no assurance
as to the